抽象的

Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors

Michael P Chu, Vijaya L Damaraju & Michael B Sawyer

Single-agent tyrosine kinase inhibitors (TKIs) have significantly improved patient outcomes across multiple tumor subtypes. However, TKI therapy is rarely curative. Early optimism of combining TKIs with cytotoxic chemotherapy failed to produce substantial results in numerous randomized studies. This article highlights potential missteps and improvements in combination therapy thus far, while shedding light on potential improvements for future combinations.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证